Histone deacetylase modulators provided by Mother Nature | Genes & Nutrition | Full Text
Known HAt inhibitors | Download Table
Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
Histone Acetyltransferase (HAT) P300/CBP Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal Cancer Cells through Destabilizing AKT
Frontiers | Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus | Cell and Developmental Biology
A Review on Important Histone Acetyltransferase (HAT) Enzymes as Targets for Cancer Therapy | Bentham Science
Histone Acetyltransferases (HATs) Involved in Non-Homologous End Joining as a Target for Radiosensitization | IntechOpen
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer | Anticancer Research
Frontiers | Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy | Oncology
HAT inhibitors and activators, their target histone acetyltransferases,... | Download Table
Inhibition of histone acetyltransferase GCN5 extends lifespan in both yeast and human cell lines - Huang - 2020 - Aging Cell - Wiley Online Library
Characterization of novel inhibitors of histone acetyltransferases | Molecular Cancer Therapeutics
KATs in cancer: functions and therapies | Oncogene
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed | Future Medicinal Chemistry
CPTH2 is a Potent Histone Acetyltransferase (HAT) Inhibitor - Network of Cancer Research
Gururaj M. Shivashimpi's Blog: Histone Deacetylase Inhibition and Cancer Therapy
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials | Signal Transduction and Targeted Therapy
Histone acetyltransferase (HAT) activation as a therapeutic strategy.... | Download Scientific Diagram
Cureus | Advances in Epigenetic Cancer Therapeutics
Cancers | Free Full-Text | Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer | HTML
HAT inhibitors in cancer therapy - ScienceDirect
Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells | Clinical Epigenetics | Full Text
